Key result
Sitagliptin shows no link to MACCE risk in ischemic stroke patients with T2DM and CKD.
Why the study?
Limited data are available regarding the cardiovascular safety and efficacy of sitagliptin in ischemic stroke patients with type 2 diabetes mellitus and chronic kidney disease.
Does sitagliptin reduce major adverse cardiac and cerebrovascular events in ischemic stroke patients with type 2 diabetes and chronic kidney disease?
Population
1375 ischemic stroke patients with T2DM and CKD
Comparison
Sitagliptin vs no sitagliptin
Design
Database-derived matched cohort study
Follow-up
Mean 1.07-year
Authors
Loading...
Sitagliptin shows no MACCE association in recent ischemic stroke patients with T2DM and CKD; leaves open DPP-4 inhibitor effects and requires randomized confirmation.
Cohort (n=1,375)
Does sitagliptin reduce major adverse cardiac and cerebrovascular events in ischemic stroke patients with type 2 diabetes and chronic kidney disease?
Hazard Ratio: 1.05 (95% CI 0.75–1.45)
Absolute Event Rate: 16.4% vs 15%
In patients with recent ischemic stroke, T2DM, and CKD, sitagliptin use was neutral regarding cardiovascular risk.
Liang et al. (2018) conducted a cohort in Ischemic stroke with type 2 diabetes mellitus and chronic kidney disease (n=1,375). Sitagliptin vs. No sitagliptin was evaluated on major adverse cardiac and cerebrovascular events (MACCE), including ischemic stroke, hemorrhagic stroke, myocardial infarction (MI), or CV death (HR 1.05, 95% CI 0.75-1.45). Sitagliptin exposure in ischemic stroke patients with T2DM and CKD was not associated with altered risk of MACCE compared to non-use (16.4% vs 15.0%; HR 1.05; 95% CI 0.75-1.45).
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: